ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Sumitomo Dainippon puts drug developed with artificial intelligence in the clinic

by Michael McCoy
February 7, 2020 | APPEARED IN VOLUME 98, ISSUE 6

 

Sumitomo Dainippon Pharma says it has initiated a Phase I clinical study in Japan of DSP-1181, a treatment for obsessive-compulsive disorder that was created using artificial intelligence technology from Exscientia. A joint research team combined Sumitomo’s expertise in monoamine GPCR drug discovery and Exscientia’s Centaur Chemist AI platform. The firms say they completed the exploratory research phase in less than 12 months, versus the typical average of 4.5 years.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment